PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Kalbe Farma Dividend Announcement
• Kalbe Farma announced a annually dividend of Rp31.00 per ordinary share which will be made payable on 2024-06-14. Ex dividend date: 2024-05-29
• Kalbe Farma annual dividend for 2024 was Rp31.00
• Kalbe Farma annual dividend for 2023 was Rp38.00
• Kalbe Farma's trailing twelve-month (TTM) dividend yield is 2.07%
• Kalbe Farma's payout ratio for the trailing twelve months (TTM) is 46.55%
• Kalbe Farma's dividend growth over the last five years (2018-2023) was 8.73% year
• Kalbe Farma's dividend growth over the last ten years (2013-2023) was 7.18% year
Kalbe Farma Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-05-29 | Rp31.00 | annually | 2024-06-14 |
2023-05-12 | Rp38.00 | annually | 2023-05-31 |
2022-05-31 | Rp35.00 | annually | 2022-06-22 |
2021-06-08 | Rp28.00 | annually | 2021-06-30 |
2020-12-04 | Rp6.00 | annually | 2020-12-18 |
2020-06-02 | Rp20.00 | annually | 2020-06-19 |
2019-06-10 | Rp26.00 | annually | 2019-06-21 |
2018-06-22 | Rp25.00 | annually | 2018-07-06 |
2017-06-13 | Rp22.00 | annually | 2017-07-07 |
2016-06-08 | Rp19.00 | annually | |
2016-06-06 | Rp19.00 | annually | |
2015-05-26 | Rp19.00 | annually | |
2014-06-16 | Rp17.00 | annually | |
2013-06-14 | Rp19.00 | annually |
Kalbe Farma Dividend per year
Kalbe Farma Dividend growth
Kalbe Farma Dividend Yield
Kalbe Farma current trailing twelve-month (TTM) dividend yield is 2.07%. Interested in purchasing Kalbe Farma stock? Use our calculator to estimate your expected dividend yield:
Kalbe Farma Financial Ratios
Kalbe Farma Dividend FAQ
Other factors to consider when evaluating Kalbe Farma as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Kalbe Farma stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Kalbe Farma's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Kalbe Farma publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Kalbe Farma distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Kalbe Farma are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Kalbe Farma sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Kalbe Farma distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Kalbe Farma declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Kalbe Farma's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Kalbe Farma's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.